GlassScriptPhysician profile
Klara Fradlis
NPI 1710181110
$2,400.47
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,880 · 2020: $506 · 2021: $14.76.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $304.09 | 2019-2020 | |
| Amarin Pharma, INC. | $300.59 | 2019-2020 | |
| Novo Nordisk INC | $246.60 | 2019-2020 | |
| Amgen INC. | $205.97 | 2019-2020 | |
| Abbvie INC. | $150.17 | 2019-2021 | |
| Astellas Pharma US INC | $140.27 | 2019 | |
| Allergan, INC. | $135.01 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.76 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.50 | 2019 | |
| Glaxosmithkline, LLC. | $86.06 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $79.36 | 2019-2020 | |
| Pfizer INC. | $77.08 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $71.66 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $70.08 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $50.48 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $42.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $40.63 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.55 | 2019 | |
| Arbor Pharmaceuticals, INC. | $31.37 | 2019-2020 | |
| Gilead Sciences, INC. | $28.35 | 2019 | |
| Radius Health, INC. | $26.70 | 2019 | |
| Lilly USA, LLC | $26.69 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.70 | 2020 | |
| Melinta Therapeutics, LLC | $20.35 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Klara Fradlis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.